AZ Inks Machine Learning Deal With BenevolentAI
Executive Summary
The company's biopharma R&D chief tells Scrip about trying to unlock the potential of the the vast amount of data produced to improve the understanding of complex disease biology and identify new targets to treat debilitating diseases.
You may also be interested in...
The Secret Sauce To BenevolentAI’s Ongoing Success
In a crowded AI-driven drug development sector, BenevolentAI stands out with its broad pipeline of drug candidates, deep pockets, and a growing partnership with AstraZeneca. Ivan Griffin, company co-founder and chief operating officer spoke with In Vivo about the formula behind the company’s successes.
Time For AI To Deliver In Drug Discovery, Says Atomwise CEO
Having signed a multi-year, multi-target agreement with Lilly worth potentially $550m, Atomwise CEO Abe Heifets tells Scrip the burden of proof is on AI practitioners to start producing relevant and actionable data.
Deal Watch: Lilly Partners With Avidity On RNA Medicines That Can Target Outside The Liver
Privately held Avidity’s platform creates antibody-oligonucleotide conjugate therapies, which build on RNAi approaches. Basilea/Forge collaboration seeks to create novel antibiotics using metalloenzyme chemistry.